ViiV Healthcare announced that FDA has accepted and granted Priority Review for a New Drug Application for investigational, injectable cabotegravir long-acting for PrEP, and an exclusive collaboration and license agreement with Shionogi & Co. Ltd. for S-365598, a third-generation investigational HIV integrase inhibitor with potential for use in ultra long-acting HIV regimens:
- FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
- ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.